Lobbying client

CEMPRA PHARMACEUTICALS INC.

Antibiotics

The register keeps a separate record of this client for every firm that files for it and every spelling of its name. All 4 of its records are shown together here.

Filings
48
Filed by
4
Reported in-house
—
Reported by firms
$1,215,000

Reported lobbying by year

The larger of in-house and firm-reported each year, $ thousands 2007 to 2017

Filings

48 filings, newest first.
Filing Filed by Amount
4th Quarter - Termination
4th Quarter 2017
THE CONAFAY GROUP, LLC $20,000 reported
3rd Quarter - Report
3rd Quarter 2017
THE CONAFAY GROUP, LLC $60,000 reported
2nd Quarter - Report
2nd Quarter 2017
THE CONAFAY GROUP, LLC $60,000 reported
1st Quarter - Report
1st Quarter 2017
THE CONAFAY GROUP, LLC $60,000 reported
4th Quarter - Report
4th Quarter 2016
THE CONAFAY GROUP, LLC $40,000 reported
4th Quarter - Termination (No Activity)
4th Quarter 2016
POLSINELLI PC $20,000 reported
3rd Quarter - Report
3rd Quarter 2016
THE CONAFAY GROUP, LLC $20,000 reported
3rd Quarter - Report
3rd Quarter 2016
POLSINELLI PC $20,000 reported
2nd Quarter - Report
2nd Quarter 2016
THE CONAFAY GROUP, LLC $20,000 reported
2nd Quarter - Report
2nd Quarter 2016
POLSINELLI PC $20,000 reported

Filed by

Each firm that has reported for this client, and the client itself where it lobbies in-house, with the reports filed and the amounts they disclose.

FirmReportsAmount
FABIANI & COMPANY 17 $525,000
THE CONAFAY GROUP, LLC 12 $380,000
POLSINELLI PC 9 $220,000
FGS GLOBAL (US) LLC (FKA FGH HOLDINGS LLC) 4 $90,000

Issues lobbied

How many report sections named each issue, counting the current version of each report.

Bills named in its filings

Bill numbers found in the filers' descriptions, most often named first.

BillCongressTimes named
H.R. 6 114th 8
H.R. 5325 114th 1
H.R. 5926 114th 1

From reports filed under the Lobbying Disclosure Act. Firms report what each client paid them; an organisation lobbying for itself reports its own expenses. Amounts count the current version of each report once.